Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim Post-Infusion of Haploidentical Stem Cells
NCT04237623Phase 2Recruiting
- Sponsor
- Northside Hospital
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in hematologic malignancy, sponsored by Northside Hospital. Started May 2020; status: recruiting.
02
Drugs
sargramostim
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04237623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237623.